Saxenda Side Effects: Delayed-Onset Adverse Events You Need to Know

Does the Saxenda label describe these as late-starting effects?

Mostly no. The label's warnings describe risks during treatment and give no week at which they begin. The adult safety data come from 5 placebo-controlled trials with 3,384 people on Saxenda and 1,941 on placebo. Treatment lasted up to 56 weeks in three trials, 52 weeks in one and 32 weeks in one, and a subset of one trial was followed for 160 weeks [1].

What the label does record is event counts and repeated measurements. A heart rate increase of more than 10 beats per minute occurred at two consecutive visits in 34% of Saxenda-treated patients versus 19% of placebo-treated patients [1]. Gallbladder events were more frequent on Saxenda than on placebo even after the degree of weight loss was taken into account [1]. The 2024 label also describes pancreatitis cases that occurred 74 and 124 days after the last dose in people who left the trials early [4].

Saxenda is liraglutide 3 mg, approved for weight management. Victoza is a separate Novo Nordisk liraglutide product for type 2 diabetes, dosed up to 1.8 mg daily [1]. The rates below are Saxenda's.

Common effects: early and often

In the adult trials, nausea occurred in 39.3% of Saxenda-treated patients versus 13.8% on placebo, diarrhea in 20.9% versus 9.9%, constipation in 19.4% versus 8.5%, and vomiting in 15.7% versus 3.9% [1]. About 68% versus 39% reported any gastrointestinal disorder, and nausea declined as treatment continued [1]. Treatment was stopped because of adverse reactions in 9.8% versus 4.3%; nausea (2.9% versus 0.2%), vomiting (1.7% versus less than 0.1%) and diarrhea (1.4% versus 0%) were the leading reasons [1]. The label says that if more than 3 days have passed since the last dose, Saxenda is restarted at 0.6 mg daily and the dose is raised again on the weekly schedule, to reduce the gastrointestinal reactions that follow reinitiation [1].

Gallbladder disease

In adult trials, cholelithiasis was reported in 2.2% of Saxenda-treated patients versus 0.8% of placebo-treated patients, and cholecystitis in 0.8% versus 0.4% [1]. Most Saxenda-treated patients with these events required cholecystectomy [1]. The label notes that substantial or rapid weight loss can itself raise gallstone risk, but that gallbladder events were still more common on Saxenda after accounting for how much weight people lost [1].

The label says that if cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated [1].

Pancreatitis

The 2024 Saxenda label reported acute pancreatitis confirmed by adjudication in 9 of 3,291 Saxenda-treated adults (0.3%) and 2 of 1,843 placebo-treated adults (0.1%) [4]. Four further cases in Saxenda-treated patients fell outside active treatment. Two occurred in people who withdrew early, 74 and 124 days after their last dose. One occurred during an off-treatment follow-up period within 2 weeks of stopping. One occurred in a patient who completed treatment and had been off treatment for 106 days [4]. In the pediatric trial, one Saxenda-treated patient (0.8%) had pancreatitis, which led to discontinuation [4].

The current label says to observe patients carefully after starting Saxenda for signs of acute pancreatitis, such as persistent or severe abdominal pain that may radiate to the back, with or without nausea or vomiting. It says to discontinue Saxenda and start appropriate management if pancreatitis is suspected [1]. The 2024 label stated that whether people with a history of pancreatitis are at higher risk on Saxenda is unknown [4].

Heart rate increase

Resting heart rate rose by a mean of 2 to 3 beats per minute on Saxenda compared with placebo [1]. More Saxenda-treated patients had changes from baseline of more than 10 bpm at two consecutive visits (34% versus 19%) and more than 20 bpm (5% versus 2%) [1]. At least one resting heart rate above 100 bpm was recorded in 6% versus 4%, and at two consecutive visits in 0.9% versus 0.3% [1]. Tachycardia was reported as an adverse reaction in 0.6% versus 0.1% [1]. In a clinical pharmacology trial with 24-hour continuous monitoring, heart rate on Saxenda ran 4 to 9 bpm above placebo, and in the pediatric trial mean resting heart rate rose 3 to 7 bpm from baseline [1].

The label says to monitor heart rate at regular intervals [1].

Thyroid C-cell tumors

This is Saxenda's boxed warning. Liraglutide caused dose- and duration-dependent thyroid C-cell tumors, including carcinomas, in rats and mice at clinically relevant exposures. Whether it causes medullary thyroid carcinoma (MTC) in humans has not been determined [1]. Saxenda is contraindicated in people with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 [1]. The label lists neck mass, difficulty swallowing, difficulty breathing and persistent hoarseness as symptoms of thyroid tumors. It states that routine serum calcitonin measurement or thyroid ultrasound is of uncertain value for early detection [1]. Postmarketing reports of MTC in liraglutide-treated patients are described in the label as insufficient to establish or exclude a causal relationship [1].

A series of trials measured calcitonin every 3 months for up to 2 years in more than 5,000 people receiving liraglutide or control therapy. Mean levels stayed at the low end of normal, with no consistent dose or time relationship and no consistent difference between groups [3]. The authors concluded the data do not support an effect of GLP-1 receptor activation on serum calcitonin in humans [3].

Mood and suicidal thoughts: what changed

Saxenda's label no longer carries a suicidal behavior and ideation warning. On 2026-01-13, FDA asked the makers of Saxenda, Wegovy and Zepbound to remove that language. FDA said a comprehensive review found no increased risk of suicidal behavior and ideation with GLP-1 receptor agonists [2]. The current Saxenda label, effective 2026-02-25, has no such warning section, and the word does not appear in its text [1]. The label dated 2024-01-26 did include it [4].

A depression rate still appears in the pediatric trial table: 4% on Saxenda versus 2.4% on placebo in adolescents aged 12 to 17 [1].

Kidney injury from volume depletion

The label's warning is acute kidney injury due to volume depletion. It says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1].

Low blood sugar

Insulin or a sulfonylurea can increase the risk of low blood sugar with Saxenda, and low blood sugar was also reported in adolescents without diabetes [1]. Among adults with type 2 diabetes taking a sulfonylurea, blood glucose below 54 mg/dL with or without symptoms occurred in 28.2% of Saxenda-treated patients versus 12.7% of placebo-treated patients, in a trial where sulfonylurea doses were cut by 50% at the start [1]. Severe hypoglycemia requiring another person's help occurred in 0.7% of Saxenda-treated patients, all on a sulfonylurea, and in no placebo patients [1]. In adolescents without diabetes, clinically significant hypoglycemia (below 54 mg/dL) occurred in 1.6% versus 0.8%, and hypoglycemia defined as below 70 mg/dL with symptoms in 15.2% versus 4% [1]. The label states the risk may be lowered by reducing the dose of the sulfonylurea or insulin [1].

Oral medicines and birth control pills

The label states that Saxenda delays gastric emptying and may affect absorption of oral medicines. In clinical pharmacology trials liraglutide did not affect absorption of the tested oral drugs to a clinically relevant degree, and the label advises monitoring for consequences of delayed absorption [1]. In an oral contraceptive study with 0.03 mg ethinylestradiol and 0.15 mg levonorgestrel, liraglutide lowered peak ethinylestradiol concentration by 12% and peak levonorgestrel by 13%. It left ethinylestradiol AUC unchanged, raised levonorgestrel AUC by 18%, and delayed time to peak by 1.5 hours [1]. Unlike tirzepatide, the Saxenda label gives no instruction to switch contraception or add a backup method [1].